GCG and early-onset autosomal dominant Alzheimer disease: In Alzheimer’s disease models, GLP-1 RAs demonstrate multiple beneficial mechanisms, including reduced amyloid-β and tau pathology through enhanced clearance mechanisms, decreased neuroinflammation by modulating microglial activation states, and enhanced synaptic plasticity through improved long-term potentiation and dendritic spine density [35,109].